News

Weekly Policy Update: Prescription Drug Importation and CBSA’s Day at the Capitol

Yesterday the Colorado BioScience Association testified in opposition to Senate Bill 005, which tasks the department of health care policy and financing to design a program to import prescription pharmaceutical products for sale to Colorado consumers. CBSA President & CEO Jennifer Jones Paton outlined the reasons the Association opposes the bill, including strong concerns about patient safety, the impact on innovation, and minimal savings for consumers. Other opponents of the bill included BIO, PhRMA, the Colorado Competitive Council, and the Colorado Chamber of Commerce.

Click here to see Denver7’s coverage of the committee hearing, which includes interviews with the bill sponsors, supporters, and opponents including CBSA’s Jennifer Jones Paton.

Senate Bill 005 passed out of the Senate Health and Human Services Committee by a vote of 4-1, and was referred to the Senate Committee on Appropriations.

CBSA will continue to meet with policymakers and partners to discuss the dangers of this bill and the impact it could have on bioscience innovation.If your company has specific examples of how an importation program would impact innovation or investment in R&D, please contact CBSA Vice President, Emily Roberts.

SAVE THE DATE

Colorado BioScience Association’s Day at the Capitol

March 4, 2019

This annual event brings life science innovators to the state Capitol to advocate for policies that support the bioscience industry and showcase the discoveries and advancements taking place across our state.

Highlights will include:

• Discussion of CBSA’s 2019 policy priorities and how that translates into action

• Opportunity to meet Colorado state legislators and showcase your company

Additional details and registration information forthcoming.

If your company is interested in participating in the company showcase, please contact CBSA Vice President, Emily Roberts.

 



Go Back